Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9136)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 24, 2019 (publication date) through Nov 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wu J, Contratto M, Shanbhogue KP, Manji GA, O’Neil BH, Noonan A, Tudor R, Lee R. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma. World J Clin Oncol 2019; 10(3): 149-160 [PMID: 30949444 DOI: 10.5306/wjco.v10.i3.149] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i3/149.htm |
| Number | Citing Articles |
| 1 |
Chengheng Liao, Qing Zhang. Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases. The American Journal of Pathology 2020; 190(8): 1584 doi: 10.1016/j.ajpath.2020.04.003
|
| 2 |
Maxwell Shulman, Rachel Shi, Qing Zhang. Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. Journal of Genetics and Genomics 2021; 48(7): 552 doi: 10.1016/j.jgg.2021.05.016
|
| 3 |
Vincent Wai-Hin Yuen, Carmen Chak-Lui Wong. Hypoxia-inducible factors and innate immunity in liver cancer. Journal of Clinical Investigation 2020; 130(10): 5052 doi: 10.1172/JCI137553
|
| 4 |
Kurt Sartorius, Samuel O. Antwi, Anil Chuturgoon, Lewis R. Roberts, Anna Kramvis. RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.891812
|
| 5 |
Zhen Luo, Mingfu Tian, Ge Yang, Qiaoru Tan, Yubing Chen, Geng Li, Qiwei Zhang, Yongkui Li, Pin Wan, Jianguo Wu. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01080-1
|
| 6 |
Roy Elias, Qing Zhang, James Brugarolas. The von Hippel-Lindau Tumor Suppressor Gene. The Cancer Journal 2020; 26(5): 390 doi: 10.1097/PPO.0000000000000480
|
| 7 |
Zhenli Li, Mingda Zhao, Xingshun Qi, Yufu Tang, Shuqun Cheng. Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma. Journal of Cellular and Molecular Medicine 2023; 27(15): 2103 doi: 10.1111/jcmm.17808
|
| 8 |
Kanchan Vishnoi, Navin Viswakarma, Ajay Rana, Basabi Rana. Transcription Factors in Cancer Development and Therapy. Cancers 2020; 12(8): 2296 doi: 10.3390/cancers12082296
|
| 9 |
Jianping Wang, Bin Zhao, Jingmin Che, Peng Shang. Hypoxia Pathway in Osteoporosis: Laboratory Data for Clinical Prospects. International Journal of Environmental Research and Public Health 2023; 20(4): 3129 doi: 10.3390/ijerph20043129
|
| 10 |
Sajad Fakhri, Seyed Zachariah Moradi, Farahnaz Faraji, Leila Kooshki, Kassidy Webber, Anupam Bishayee. Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review. Cancer and Metastasis Reviews 2024; 43(1): 501 doi: 10.1007/s10555-023-10136-9
|
| 11 |
Xiaoyu Sun, Xuemei Lv, Yuanyuan Yan, Yanyun Zhao, Rong Ma, Miao He, Minjie Wei. Hypoxia-mediated cancer stem cell resistance and targeted therapy. Biomedicine & Pharmacotherapy 2020; 130: 110623 doi: 10.1016/j.biopha.2020.110623
|
| 12 |
Mohammed Hussein Assi. Hypoxia-inducible Factors: Molecular Basis and Clinical Implications. Mustansiriya Medical Journal 2023; 22(2): 161 doi: 10.4103/mj.mj_38_23
|
| 13 |
Gulnihal Ozcan. The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1082057
|
| 14 |
David Roig-Carles, Holly Jackson, Katie F. Loveson, Alan Mackay, Rebecca L. Mather, Ella Waters, Massimiliano Manzo, Ilaria Alborelli, Jon Golding, Chris Jones, Helen L. Fillmore, Francesco Crea. The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation. International Journal of Molecular Sciences 2021; 22(17): 9165 doi: 10.3390/ijms22179165
|
| 15 |
Ruixue Bai, Yunong Li, Lingyan Jian, Yuehui Yang, Lin Zhao, Minjie Wei. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Molecular Cancer 2022; 21(1) doi: 10.1186/s12943-022-01645-2
|
| 16 |
Shant Qinxiang Sin, Chakrabhavi Dhananjaya Mohan, Robby Miguel Wen-Jing Goh, Mingliang You, Siddaiah Chandra Nayak, Lu Chen, Gautam Sethi, Kanchugarakoppal Subbegowda Rangappa, Lingzhi Wang. Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities. Cancer and Metastasis Reviews 2023; 42(3): 741 doi: 10.1007/s10555-022-10071-1
|
| 17 |
Xin Wang, Zhen-wu Du, Tian-min Xu, Xiao-jun Wang, Wei Li, Jia-li Gao, Jing Li, He Zhu. HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.785111
|
| 18 |
Corbin C. Jensen, Noel A. Warfel. Comprehensive Pharmacology. 2022; : 438 doi: 10.1016/B978-0-12-820472-6.00039-6
|
| 19 |
Cemre Ucaryilmaz Metin, Gulnihal Ozcan. The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer. Cancers 2022; 14(11): 2711 doi: 10.3390/cancers14112711
|
| 20 |
Anne Noonan, Timothy M. Pawlik. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opinion on Investigational Drugs 2019; 28(11): 941 doi: 10.1080/13543784.2019.1677606
|
| 21 |
Manish Pandey, Divya Ojha, Sakshi Bansal, Ambadas B. Rode, Geetanjali Chawla. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine 2021; 81: 101003 doi: 10.1016/j.mam.2021.101003
|
| 22 |
Prithi Raguraman, Akilandeswari Ashwini Balachandran, Suxiang Chen, Sarah D. Diermeier, Rakesh N. Veedu. Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation. Cancers 2021; 13(21): 5555 doi: 10.3390/cancers13215555
|
| 23 |
Xiaoyi Yuan, Wei Ruan, Bentley Bobrow, Peter Carmeliet, Holger K. Eltzschig. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nature Reviews Drug Discovery 2024; 23(3): 175 doi: 10.1038/s41573-023-00848-6
|
| 24 |
Yang Liu, Ruyi Xu, Huiyao Gu, Enfan Zhang, Jianwei Qu, Wen Cao, Xi Huang, Haimeng Yan, Jingsong He, Zhen Cai. Metabolic reprogramming in macrophage responses. Biomarker Research 2021; 9(1) doi: 10.1186/s40364-020-00251-y
|
| 25 |
Shilin Wang, Guohong Liu, Yirong Li, Yunbao Pan. Metabolic Reprogramming Induces Macrophage Polarization in the Tumor Microenvironment. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.840029
|
| 26 |
Mohammad Javad Kamali, Mohammad Salehi, Somayeh Fatemi, Fereshteh Moradi, Azin Khoshghiafeh, Mohamadreza Ahmadifard. Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment. Experimental Cell Research 2023; 423(1): 113442 doi: 10.1016/j.yexcr.2022.113442
|
| 27 |
Jianying Li, Chelsea Bolyard, Gang Xin, Zihai Li. Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.747863
|
| 28 |
Yao Chen, Dong Zhao, Feng Xiao, Xuanyu Li, Jia'an Li, Zhenwei Su, Xingyu Jiang. Microfluidics‐enabled Serial Assembly of Lipid‐siRNA‐sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. Advanced Materials 2023; 35(13) doi: 10.1002/adma.202209672
|
| 29 |
Yukari Shirai, Christalle C. T. Chow, Gouki Kambe, Tatsuya Suwa, Minoru Kobayashi, Itsuki Takahashi, Hiroshi Harada, Jin-Min Nam. An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor. Cancers 2021; 13(11): 2813 doi: 10.3390/cancers13112813
|